InvestorsHub Logo
Followers 523
Posts 6631
Boards Moderated 1
Alias Born 07/24/2012

Re: None

Wednesday, 10/10/2012 10:54:24 PM

Wednesday, October 10, 2012 10:54:24 PM

Post# of 130503
Advancing MANF as a disease-modifying treatment for Parkinson’s disease continues to be our primary focus. We anticipate announcing interim results from on-going delivery experiments by the end of October. The Company is working to secure funding to advance MANF towards an Investigational New Drug filing for Parkinson’s disease with the Food and Drug Administration.